Retrophin raises $25m to fund new deal, advance pipeline
This article was originally published in Scrip
Executive Summary
Orphan disease-focused pharmaceutical company Retrophin raised $25 million from a private placement of stock and warrants to fund its obligations under a new licensing agreement and to advance its lead drug candidate RE-021 and other programs.